ABSTRACT
Poor solubility and cationic amphiphilic drug-likeness were liabilities identified for a lead series of S1P3-sparing, S1P1 agonists originally developed from a high-throughput screening campaign. This work describes the subsequent optimization of these leads by balancing potency, selectivity, solubility and overall molecular charge. Focused SAR studies revealed favorable structural modifications that, when combined, produced compounds with overall balanced profiles. The low brain exposure observed in rat suggests that these compounds would be best suited for the potential treatment of peripheral autoimmune disorders.
Subject(s)
Oxadiazoles/pharmacology , Receptors, Lysosphingolipid/agonists , Thiadiazoles/pharmacology , Animals , Brain/metabolism , Glutamic Acid/metabolism , Hep G2 Cells , Humans , Hydrogen Bonding , Kinetics , Oxadiazoles/blood , Oxadiazoles/chemical synthesis , Rats , Solubility , Structure-Activity Relationship , Thiadiazoles/blood , Thiadiazoles/chemical synthesisABSTRACT
The discovery of a new series of selective S1P1 agonists is described. This series of piperazinyl-oxadiazole derivatives was rapidly optimized starting from high-throughput screening hit 1 to afford potent and selective lead compound 10d. Further SAR studies showed that 10d was converted to the active phosphate metabolite 29 in vivo. Oral administration of compound 10d to rats was shown to induce lymphopenia at 3 mg/kg.
